Design Therapeutics (DSGN)

Executive Summary

Design Therapeutics (NASDAQ: DSGN) is a biotechnology company developing novel GeneTAC™ small molecule therapies targeting the root cause of degenerative diseases driven by nucleotide repeat expansions. Its lead program, DT-216, is in development for Friedreich Ataxia (FA), a devastating neurodegenerative disorder. The company has completed two Phase 1 trials of DT-216 and initiated a Phase 1/2 study (NCT06874010) in June 2025, with a primary completion date of March 2027. Additionally, DT-216P2, an optimized formulation, is being evaluated in a separate Phase 1 study (NCT06772870) that completed enrollment in December 2025, with data expected to be presented. Beyond FA, Design is advancing DT-168 for Fuchs Endothelial Corneal Dystrophy, which is currently in a Phase 2 trial (NCT07024693) with top-line data anticipated by late 2026. The company’s platform also targets myotonic dystrophy type 1 and Huntington’s disease, providing a broad pipeline with multiple potential value inflections over the next 12-18 months.

Upcoming Catalysts (preview)

• H2 2026DT-216 Phase 1/2 Interim Data60% success
• Q4 2026DT-168 Phase 2 Top-Line Results in Fuchs Dystrophy55% success
• H2 2026DT-216P2 Phase 1 Data Presentation65% success